Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023
Sanyou launches new European offices and continues to promote global business landscape
Intensity Therapeutics’ INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas
High Schooler empowers Youth with Nonprofit “Unlimited Potential”, raises $100,000 for Sports Medicine Research and Advocacy
Gas-propelled Devices are Expected to be Fastest Growing Segment
America’s Best Wings: Everything You Need to Know
Health: what is cupping, this cupping therapy practiced by Karim Benzema?
Study by Didier Raoult on hydroxychloroquine: the Medicines Agency will take legal action
Mother’s Day: Are you late? Here are 4 last minute gift ideas
Cahors. Two days on road safety for seniors
Masseube: workshops to prevent falls
Initial data showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refractory gastric cancer expressing Claudin 18.2, with a well-tolerated safety profile Elevation...